Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Study of Longitudinal Plasma PD-L1 Testing With Immunotherapy in Lung Cancer

NCT06849518 · View on ClinicalTrials.gov ↗

Study Summary

This is a prospective pilot study to assess dynamic changes of plasma cell-free RNA (cfRNA) PD-L1 expression in patients with lung cancer undergoing immune checkpoint inhibitor (ICI) based therapy. Results will be correlated with radiographic assessment of immunotherapy treatment response and plasma NGS ctDNA.

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST Circulogene liquid biopsy testing

Study Locations (1)

Tennessee

  • Ballad Health Cancer Care — Kingsport

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-02-11
Est. Completion 2027-03-01
Phase NA

Sponsor

Ballad Health

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06849518

The ClinicalTrials.gov registry entry for NCT06849518 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ballad Health, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 1 intervention — of which Circulogene liquid biopsy testing is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06849518 reports 1 study location spanning 1 distinct geographic area — top geographies include Tennessee. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06849518 about?

NCT06849518 is a clinical study titled "Study of Longitudinal Plasma PD-L1 Testing With Immunotherapy in Lung Cancer". This is a prospective pilot study to assess dynamic changes of plasma cell-free RNA (cfRNA) PD-L1 expression in patients with lung cancer undergoing immune checkpoint inhibitor (ICI) based therapy. Results will be correlated with radiographic assessment of immunotherapy treatment response and plasma...

What is the current status of trial NCT06849518?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-02-11. Estimated completion is 2027-03-01.

What conditions does trial NCT06849518 study?

This clinical trial studies the following conditions: Lung Cancer (NSCLC). These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06849518?

The interventions under investigation include: Circulogene liquid biopsy testing (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06849518?

This trial is sponsored by Ballad Health, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06849518 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial